Danazol increases T regulatory cells in patients with aplastic anemia
article
OA: gold
CC0
⤵ 4 in-corpus citations
AI-generated summary
This study found that patients with aplastic anemia have lower T regulatory cells than healthy controls, and Danazol treatment significantly increases these cells in patients.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVES: FoxP3+ T regulatory cells (T-regs) in the pathophysiology of AA and their response to treatment with Danazol alone or in combination with immunosuppressive treatment (IST). METHODS: T-regs' percentages of 25 acquired idiopathic AA patients and 25 healthy controls who completed study protocol were analyzed by performing multicolor flowcytometry on peripheral blood samples. RESULTS: More than one-third (36%) of AA patients in our study received Danazol as monotherapy, whereas less than a third (32%) each received standard doses of IST with equine Anti Thymocyte Globulin (ATG) and Cyclosporine combination, or Cyclosporine and Danazol combination, respectively. Results showed that all AA patients had a significantly lower percentage of T-regs at the time of diagnosis when compared to healthy controls (p < 0.0001), implicating their role in the pathophysiology. On treatment, all 25 patients showed a significant rise in the percentage of T-regs when compared to baseline (p < 0.0001). DISCUSSION: The rise in T-regs' percentage was higher in patients treated with Danazol alone when compared to standard IST (ATG with Cyclosporine), or Cyclosporine with Danazol combinations (p = 0.585). CONCLUSION: We conclude that Danazol also leads to increase in T-regs in acquired idiopathic AA.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Danazol as first-line therapy for aplastic anemia 2011
- Danazol therapy for aplastic anemia refractory to immunosuppressive therapy 2007
- Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia 2000
- Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia 2000
Cited by (4)
- Danazol 2022
- [Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells]. 2022
- Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia 2025
- Stanozolol and Danazol Have Different Effects on Hematopoiesis in the Murine Model of Immune-Mediated Bone Marrow Failure 2021
References (24)
- Danazol as first-line therapy for aplastic anemia via openalex
- Danazol therapy for aplastic anemia refractory to immunosuppressive therapy via openalex
- Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia via openalex
- Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia via openalex
- W2385349793 via openalex
- W2392480230 via openalex
- doi:10.1182/blood.v106.11.2276.2276 via openalex
- doi:10.1182/blood-2011-08-368308 via openalex
- doi:10.1093/pubmed/fdv027 via openalex
- doi:10.1681/asn.2006050422 via openalex
- doi:10.1182/blood-2016-03-703702 via openalex
- doi:10.3109/10428194.2012.728287 via openalex
- doi:10.4274/tjh.2013.0410 via openalex
- doi:10.1007/s00277-012-1448-8 via openalex
- doi:10.1182/blood-2004-12-4589 via openalex
- doi:10.1182/blood-2006-03-010777 via openalex
- doi:10.1182/blood-2007-01-066258 via openalex
- doi:10.1179/1607845414y.0000000196 via openalex
- doi:10.1159/000040999 via openalex
- doi:10.1182/blood-2010-01-266098 via openalex
- doi:10.1111/j.1365-2141.1993.tb04645.x via openalex
- W658890514 via openalex
- doi:10.1182/blood-2011-11-390708 via openalex
- doi:10.1016/j.cellimm.2015.04.001 via openalex
Cited by (4)
- Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia 2025
- [Efficacy of stanozolol and danazol in the treatment of non-severe aplastic anemia and their effects on CD4(+)CD25(+)Foxp3(+) regulatory T cells]. 2022
- Danazol 2022
- Stanozolol and Danazol Have Different Effects on Hematopoiesis in the Murine Model of Immune-Mediated Bone Marrow Failure 2021
Source provenance
- openalex
- last seen: 2026-05-10T11:10:41.912031+00:00
License: CC0
· commercial use OK